{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:35Z","timestamp":1789496075160,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed to determine the long-term effectiveness and safety of natalizumab in an EID setting in a cohort of patients with multiple sclerosis (MS) treated for more than 7 years. We conducted an observational retrospective cohort study, including 39 (34 female, 5 male) patients with clinically definite relapsing-MS, initially treated with standard interval dosing (SID) of natalizumab (mean time 54 months [SD29]) who were then switched to EID, every 8 weeks (mean time 76 months [SD13]). The main outcome measures included the following: i) annualized relapse rate (ARR), ii) radiological activity, iii) disability progression, and iv) NEDA-3 no evidence of disease activity index. EID preserved ARR, radiological activity, and prevented disability worsening during follow-up. The proportion of patients maintaining their NEDA-3 status after 24, 48, and 72 months of natalizumab administration in EID was 94%, 73%, and 70%, respectively. Stratified analysis according to history of drug therapy showed that the EID of natalizumab was slightly more effective in na\u00efve patients than in those previously treated with other immunosuppressive drugs. No cases of PML or other severe adverse reactions were reported. In conclusion, long-term therapy with natalizumab in an EID setting following an SID regimen maintained its disease-modifying activity, and was safe and well tolerated for over 7 years. These encouraging observational results need to be confirmed in controlled clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2021.614715","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T07:51:50Z","timestamp":1616658710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Javier","family":"Riancho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Setien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ram\u00f3n","family":"S\u00e1nchez de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Barquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Misiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Castillo-Trivi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Men\u00e9ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Delgado-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"Stuve","year":"2007","journal-title":"CNS Drug Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0541-5","article-title":"Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis","volume":"32","author":"Lucchetta","year":"2018","journal-title":"CNS Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007451","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in Germany","volume":"92","author":"Blankenbach","year":"2019","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2019","journal-title":"Mult Scler"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03959-4","article-title":"Four cases of natalizumab-related PML: a less severe course in extended interval dosing","volume":"40","author":"Scarpazza","year":"2019","journal-title":"Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200206000-00003","article-title":"The clinico-radiological paradox in multiple sclerosis revisited","volume":"15","author":"Barkhof","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00710","article-title":"Remodeling functional connectivity in multiple sclerosis: a challenging therapeutic approach","volume":"11","author":"Stampanoni Bassi","year":"2017","journal-title":"Front Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00212-5","article-title":"A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.614715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T07:51:51Z","timestamp":1616658711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.614715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2021.614715"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.614715","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"article-number":"614715"}}